乙酰半胱氨酸镁盐-甘草酸环状样二聚体治疗大鼠肝纤维化的实验研究  

Experimental study of acetylcysteine magnesium-glycyrrhizin fine antipode dimers on rat liver fibrosis

作　　者：庄让笑[1] 王福根[1] 邵益丹[1] 方红英[1] 孙晶晶[1] 席建军[1] 潘金明[1] 梁伟峰[2] 刘寿荣[1] 

机构地区：[1]浙江中医药大学附属西溪医院 [2]浙江大学医学院附属第一医院

出　　处：《中国临床药理学与治疗学》2014年第12期1337-1341,共5页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：浙江省自然科学基金项目(Y2101449);杭州市科技发展计划项目(20100733Q13)

摘　　要：目的:研究新合成产物乙酰半胱氨酸镁盐-甘草酸环状样二聚体(acetylcysteine magnesiumglycyrrhizin fine antipode dimers,GFA-NAC·Mg)治疗大鼠肝纤维化的效果。方法:25%四氯化碳(CCl4)制备大鼠肝纤维化模型,GFA-NAC·Mg按25、50、100mg/kg剂量每日分别腹腔注射进行肝纤维化治疗,给药8周后处死大鼠,用肝纤维化网格染色观察肝纤维化情况,ELISA法测定血清羟脯氨酸(Hyp)和肝组织丙二醛(MDA)、超氧化物歧化酶(SOD)、转化生长因子-β1(TGF-β1)、血小板衍生生长因子(PDGF)。结果:大鼠肝组织病理结果显示其肝纤维化处于Ⅲ-Ⅳ期;与模型组比较,GFA-NAC·Mg治疗后血清Hyp明显降低;肝组织抗氧化指标SOD显著升高,MDA明显下降;肝纤维化指标TGF-β1、PDGF在组织含量下降;GFA-NAC·Mg各组网格染色显示肝纤维化好转。结论:GFA-NAC·Mg对肝纤维化大鼠有较好实验治疗作用,可能通过抑制PDGF和TGF-β1的表达而实现。AIM：To investigate efficacy of GFA-NAC · Mg on rat liver fibrosis.METHODS：Preparation of liver fibrosis model in rats with 25% carbontetrachloride （CCl4） by subcutaneous injection,GFA-NAC · Mg intraperitoneal injected treating liver fibrosis with 25,50 and 100 mg/kg.All the rats were killed after 8 weeks of administration with grid staining and the levels of Hyp in serum were detected with ELISA assay,the contents of the MDA,SOD,TGF-β1,PDGF for liver fibrosis and liver tissue were tested.RESULTS：The liver tissue of fibrosis showed stage Ⅲ-Ⅳ.Compared with the model group,the serum of Hyp significantly was reduced after GFA-NAC · Mg treatment.The antioxidant index SOD significantly was increased in liver tissue while MDA was decreased.Liver fibrosis markers TGF-β1 and PDGF content were decreased.Liver fibrosis was improved after GFA-NAC· Mg treatment in each groups by grid staining.CONCLUSION：GFA-NAC · Mg has a better therapeutic effect on rat liver fibrosis by inhibiting the expression of PDGF and TGF-β1.

关 键 词：酰半胱氨酸镁盐-甘草酸环状样二聚体 肝纤维化 血小板衍生生长因子 转化生长因子-β1 

分 类 号：R965.2[医药卫生—药理学]